论文部分内容阅读
主要观察了ＩＬ－１２与ＩＬ－２联合对健康人和肿瘤病人ＰＢＭＣ增殖和体外杀瘤活性的影响。实验结果表明，单独应用ＩＬ－１０２对肿瘤病人ＰＨＡ活化ＰＢＭＣ增殖活性很小，如与低剂量ＩＬ－２合用，则可明显促进其增殖效应，表明ＩＬ－２可增强ＩＬ－１２的作用。与单用ＩＬ－１２相比，当ＩＬ－１２与低浓度ＩＬ－２合用时，健康人和肿瘤病人ＰＢＭＣ对Ｋ５６２细胞和Ｒａｊｉ细胞的杀伤活性均明显增强，且对Ｋ５６２细胞株杀伤活性明显强于对Ｒａｊｉ细胞株的杀伤活性。上述结果表明，ＩＬ－１２与ＩＬ－２合用对健康人和肿瘤病人ＰＢＭＣ增殖及杀瘤活性影响的格局基本一致。本实验为进一步研究ＩＬ－１２协同其它因子增强肿瘤病人ＬＭ和ＴＩＬ等免疫细胞抗肿瘤效应并进而使ＩＬ－１２过渡到临床肿瘤病人治疗提供了重要的实验依据。
Mainly observed IL-12 and IL-2 in healthy people and tumor patients PBMC proliferation and in vitro tumorigenicity. The results showed that IL-102 alone had a small proliferative activity on PHA-activated PBMC in tumor patients, such as IL-2 combined with low-dose IL-102, could significantly promote the proliferation of IL-12, indicating that IL-2 can enhance the effect of IL-12. Compared with IL-12 alone, when IL-12 was combined with low concentration of IL-2, the cytotoxic activity of PBMCs on both K562 and Raji cells was significantly increased in healthy and cancer patients, and the cytotoxicity against K562 cells was significantly higher On the Raji cell line killing activity. The above results show that the combination of IL-12 and IL-2 on healthy and tumor patients with PBMC proliferation and tumor-killing activity of the pattern is basically the same. This experiment provides an important experimental basis for further study on the antitumor effect of IL-12 and other factors in enhancing the anti-tumor effect of immune cells such as LM and TIL in tumor patients and further transplanting IL-12 to clinical tumor patients.